top of page
  • Active, not recruiting

NCT05000450: Phase 1/2: Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell RRMM

Updated: Feb 10

  • IGNITE STUDY - ALLO-605: IGNITE STUDY UTILIZING FIRST TurboCAR™ TO TARGET BCMA

  • NCT05000450: Phase 1/2: Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma


allo 605 allo 647


The purpose of the ALLO-605-201 study is to assess the safety, efficacy, and cell kinetics of ALLO605 in adults with relapsed or refractory multiple myeloma after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, and ALLO-647.


Sponsor


Locations

United States, Colorado

United States, Texas

 

ClinicalTrials.gov Identifier: NCT05000450

Official Title: A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-647 and ALLO-605, an Anti- BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

First Posted : August 11, 2021

Click here to see details on ClinicalTrials.gov

 

Genetic: ALLO-605

Biological: ALLO-647

Drug: Fludarabine

Drug: Cyclophosphamide

 

Allogeneic Anti-BCMA CAR T Cells ALLO-605 (Code C182066)

ALLO 605

ALLO-605

ALLO605

Allogeneic Anti-BCMA CAR T Cells ALLO-605

Allogeneic Anti-BCMA CAR-T Cells ALLO-605

Allogeneic Anti-BCMA TRAC/CD52-edited CAR T Cells ALLO-605

Allogeneic BCMA TurboCAR T Cells ALLO-605

 

Anti-CD52 Monoclonal Antibody ALLO-647 (Code C160787)

ALLO 647

ALLO-647

ALLO647

Anti-CD52 Monoclonal Antibody ALLO-647

 

Locations

United States, Colorado

United States, Texas






Comments


Commenting has been turned off.
Posts Archive
bottom of page